Company
Verici Dx plc
Headquarters: Penarth, United Kingdom
Employees: 10
CEO: Ms. Sara Barrington A.C.A., A.C.I.M.
Market Cap
£10.2 Million
GBP as of Jan. 1, 2025
US$12.9 Million
Verici Dx plc Categories
United Kingdom Healthcare Diagnostics & ResearchUnited Kingdom Healthcare United Kingdom Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $219.88 B |
| Danaher | $177.43 B |
| Siemens Healthineers AG | $59.19 B |
| Agilent Technologies, Inc. | $43.57 B |
| Lonza Group Ltd | $41.66 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.
Stocks & Indices
Verici Dx plc has the following listings and related stock indices.
Stock: LSE: VRCI wb_incandescent